Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma

Cancer

Volumn 106, Issue 3, 2006, Pages 703-707

  Bisogno, Gianni ^a   Riccardi, Riccardo ^b   Ruggiero, Antonio ^b   Arcamone, Giampaolo ^c   Prete, Arcangelo ^d   Surico, Gianmarco ^e   Provenzi, Massimo ^f   Bertolini, Patrizia ^g   Paolucci, Paolo ^h   Carli, Modesto ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c POLICLINICO   (Italy)

^d Paediatrics Department   (Italy)

^e Hospital of Lecce   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g UNIVERSITY HOSPITAL OF PARMA   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Desmoplastic small round cell tumor; Irinotecan; Peripheral neuroectodermal tumor; Rhabdomyosarcoma; Soft tissue sarcoma

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; IRINOTECAN;

ADOLESCENT; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANDIDIASIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; ENZYME INHIBITION; FEMALE; FEVER; HUMAN; INTESTINE INFECTION; ITALY; MALE; NEUROECTODERM TUMOR; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REMISSION; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; NEUTROPENIA; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 31544451582     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21629     Document Type: Article

References (10)

1. Boisseau M, Guichard S, Canal P, Bugat R. Irinotecan (CPT-11): current status and perspectives. Exp Opin Invest Drugs. 1996;5:613-626.
2. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393-403.
3. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumor and neuroblastoma xenografts. Br J Cancer. 1996;74:537-545.
4. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999;17: 1815-1824.
5. Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002;24:101-105.
6. Blaney S, Berg SL, Pratt C et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001;7:32-37.
7. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21:3844-3852.
8. Blaney SM, Needle MN, Gillespie A, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998;4:357-360.
9. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolamide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004;10: 840-848.
10. Rosoff PM, Bayliff S. Successful clinical response to irinotecan in desmoplastic round blue cell tumor. Med Pediatr Oncol. 1999;33:500-503.